<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39485635</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1920-7476</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Nov</Month><Day>01</Day></PubDate></JournalIssue><Title>Canadian journal of public health = Revue canadienne de sante publique</Title><ISOAbbreviation>Can J Public Health</ISOAbbreviation></Journal><ArticleTitle>Factors associated with the development, severity, and resolution of post COVID-19 condition in adults living in Canada, January 2020 to August 2022.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.17269/s41997-024-00958-7</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">We aimed to characterize the burden of post COVID-19 condition (PCC) among adults in Canada and identify factors associated with its occurrence, severity, and resolution.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We used self-report data from a population-based cross-sectional probability survey of adults in Canada conducted between April and August 2022. Incidence and prevalence of PCC were estimated using confirmed infections, as well as confirmed and suspected combined. Multivariable modeling using confirmed cases identified associated factors.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">As of August 2022, 17.2% (95% CI 15.7, 18.8) of adults with confirmed infections and 16.7% (95% CI 15.5, 18.0) of adults with confirmed or suspected infections experienced PCC, translating to 3.3% (95% CI 3.0, 3.6) and 4.4% (95% CI 4.1, 4.8) of all adults, respectively. Age less than 65&#xa0;years (aORs of 1.75 to 2.14), more pre-existing comorbidities (aORs of 1.75 to 3.57), and a more severe initial infection (aORs of 3.52 to 9.69) were all associated with higher odds of PCC, while male sex at birth (aOR&#x2009;=&#x2009;0.54, 95% CI 0.41, 0.70), identifying as Black (aOR&#x2009;=&#x2009;0.23, 95% CI 0.11, 0.51), and being infected after 2020 (aORs of 0.24 to 0.55) were associated with lower odds. Those residing in a rural area (aOR&#x2009;=&#x2009;2.31, 95% CI 1.35, 3.93), or reporting a disability (aOR&#x2009;=&#x2009;2.87, 95% CI 1.14, 7.25), pre-existing chronic lung condition (aOR&#x2009;=&#x2009;5.47, 95% CI 1.85, 16.12) or back problem (aOR&#x2009;=&#x2009;2.34, 95% CI 1.26, 4.36), or PCC headache (aOR&#x2009;=&#x2009;2.47, 95% CI 1.60, 3.83) or weakness (aOR&#x2009;=&#x2009;2.27, 95% CI 1.41, 3.68) had higher odds of greater limitations in daily activities, while males had lower odds (aOR&#x2009;=&#x2009;0.54, 95% CI 0.34, 0.85). Two or more pre-existing chronic conditions (aHRs from 0.33 to 0.38), or PCC symptoms relating to the heart (aHR&#x2009;=&#x2009;0.25, 95% CI 0.07, 0.90), brain fog (aHR&#x2009;=&#x2009;0.44, 95% CI 0.23, 0.86), or stress/anxiety (aHR&#x2009;=&#x2009;0.48, 95% CI 0.24, 0.96) were associated with a decreased rate of symptom resolution.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Over the first two and a half&#xa0;years of the pandemic, a substantial proportion of infected adults in Canada reported PCC. Females and people with comorbidities were disproportionately impacted.</AbstractText><CopyrightInformation>&#xa9; 2024. Crown.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zakaria</LastName><ForeName>Dianne</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-8610-1248</Identifier><AffiliationInfo><Affiliation>Centre for Surveillance and Applied Research, Health Promotion and Chronic Disease Prevention Branch, Public Health Agency of Canada, Ottawa, ON, Canada. dianne.zakaria@phac-aspc.gc.ca.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Demers</LastName><ForeName>Alain</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre for Surveillance and Applied Research, Health Promotion and Chronic Disease Prevention Branch, Public Health Agency of Canada, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheta</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-8600-9935</Identifier><AffiliationInfo><Affiliation>Centre for Surveillance and Applied Research, Health Promotion and Chronic Disease Prevention Branch, Public Health Agency of Canada, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aziz</LastName><ForeName>Samina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Centre for Surveillance and Applied Research, Health Promotion and Chronic Disease Prevention Branch, Public Health Agency of Canada, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdullah</LastName><ForeName>Peri</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Centre for Surveillance and Applied Research, Health Promotion and Chronic Disease Prevention Branch, Public Health Agency of Canada, Ottawa, ON, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Can J Public Health</MedlineTA><NlmUniqueID>0372714</NlmUniqueID><ISSNLinking>0008-4263</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><OtherAbstract Type="Publisher" Language="fre"><AbstractText>R&#xe9;SUM&#xe9;: OBJECTIFS: Nous avons cherch&#xe9; &#xe0; caract&#xe9;riser le fardeau du syndrome post-COVID-19 (SPC) chez les adultes au Canada et &#xe0; identifier les facteurs associ&#xe9;s &#xe0; son apparition, sa gravit&#xe9; et sa r&#xe9;solution. M&#xe9;THODES: Nous avons utilis&#xe9; les donn&#xe9;es d&#x2019;auto-&#xe9;valuation d&#x2019;une enqu&#xea;te probabiliste transversale bas&#xe9;e sur la population d&#x2019;adultes au Canada men&#xe9;e entre avril et ao&#xfb;t 2022. L&#x2019;incidence et la pr&#xe9;valence du SPC ont &#xe9;t&#xe9; estim&#xe9;es &#xe0; l&#x2019;aide d&#x2019;infections confirm&#xe9;es, ainsi que d&#x2019;infections confirm&#xe9;es et soup&#xe7;onn&#xe9;es combin&#xe9;es. La mod&#xe9;lisation multivari&#xe9;e &#xe0; l&#x2019;aide des cas confirm&#xe9;s a permis d&#x2019;identifier des facteurs leur &#xe9;tant associ&#xe9;s. R&#xe9;SULTATS: En ao&#xfb;t 2022, 17,2% (IC &#xe0; 95%: 15,7, 18,8) des adultes atteints d&#x2019;infections confirm&#xe9;es et 16,7% (IC &#xe0; 95%: 15,5, 18,0) des adultes atteints d&#x2019;infections confirm&#xe9;es ou soup&#xe7;onn&#xe9;es ont d&#xe9;velopp&#xe9; un SPC, soit 3,3% (IC &#xe0; 95%: 3,0, 3,6) et 4,4% (IC &#xe0; 95%: 4,1, 4,8) de tous les adultes, respectivement. &#xca;tre &#xe2;g&#xe9; de moins de 65 ans (aRC de 1,75 &#xe0; 2,14), un plus grand nombre de comorbidit&#xe9;s pr&#xe9;existantes (aRC de 1,75 &#xe0; 3,57) et une infection initiale plus grave (aRC de 3,52 &#xe0; 9,69) &#xe9;taient tous associ&#xe9;s &#xe0; une probabilit&#xe9; plus &#xe9;lev&#xe9;e de SPC, alors qu&#x2019;&#xea;tre un gar&#xe7;on &#xe0; la naissance (aRC&#x2009;=&#x2009;0,54, IC &#xe0; 95%: 0,41, 0,70), s&#x2019;identifier comme Noir (aRC&#x2009;=&#x2009;0,23, IC &#xe0; 95%: 0,11, 0,51) et le fait d&#x2019;&#xea;tre infect&#xe9; apr&#xe8;s 2020 (aRC de 0,24 &#xe0; 0,55) &#xe9;taient associ&#xe9;s &#xe0; des probabilit&#xe9;s plus faibles. Les personnes r&#xe9;sidant dans une r&#xe9;gion rurale (aRC&#x2009;=&#x2009;2,31, IC &#xe0; 95%: 1,35 &#xe0; 3,93) ou d&#xe9;clarant une incapacit&#xe9; (aRC&#x2009;=&#x2009;2,87, IC &#xe0; 95%: 1,14 &#xe0; 7,25), une affection pulmonaire chronique pr&#xe9;existante (aRC&#x2009;=&#x2009;5,47, IC &#xe0; 95%: 1,85 &#xe0; 16,12), des probl&#xe8;mes de dos (aRC&#x2009;=&#x2009;2,34, IC &#xe0; 95%: 1,26 &#xe0; 4,36), des maux de t&#xea;te li&#xe9;s au SPC (aRC&#x2009;=&#x2009;2,47, IC &#xe0; 95%: 1,60 &#xe0; 3,83) ou une faiblesse li&#xe9;e au SPC (aRC&#x2009;=&#x2009;2,27, IC &#xe0; 95%: 1,41, 3,68) avaient une probabilit&#xe9; plus &#xe9;lev&#xe9;e de limitations plus importantes des activit&#xe9;s quotidiennes, tandis que les hommes avaient une probabilit&#xe9; plus faible (aRC&#x2009;=&#x2009;0,54, IC &#xe0; 95%: 0,34, 0,85). Le fait d&#x2019;avoir deux maladies chroniques pr&#xe9;existantes ou plus (aRR de 0,33 &#xe0; 0,38) ou des sympt&#xf4;mes de SPC li&#xe9;s au c&#x153;ur (aRR&#x2009;=&#x2009;0,25, IC &#xe0; 95%: 0,07, 0,90), au brouillard c&#xe9;r&#xe9;bral (aRR&#x2009;=&#x2009;0,44, IC &#xe0; 95%: 0,23, 0,86) ou au stress/anxi&#xe9;t&#xe9; (aRR&#x2009;=&#x2009;0,48, IC &#xe0; 95%: 0,24, 0,96) &#xe9;taient associ&#xe9;s &#xe0; une diminution du taux de r&#xe9;solution des sympt&#xf4;mes. CONCLUSION: Au cours des deux premi&#xe8;res ann&#xe9;es et demie de la pand&#xe9;mie, une proportion importante d&#x2019;adultes infect&#xe9;s au Canada a d&#xe9;clar&#xe9; un SPC. Les femmes et les personnes avec des comorbidit&#xe9;s ont &#xe9;t&#xe9; touch&#xe9;es de mani&#xe8;re disproportionn&#xe9;e.</AbstractText><CopyrightInformation>&#xa9; 2024. Crown.</CopyrightInformation></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Canada</Keyword><Keyword MajorTopicYN="N">Cross-sectional survey</Keyword><Keyword MajorTopicYN="N">Incidence</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Multivariable modeling</Keyword><Keyword MajorTopicYN="N">Post COVID-19 condition</Keyword><Keyword MajorTopicYN="N">Prevalence</Keyword><Keyword MajorTopicYN="N">Resolution</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Severity</Keyword><Keyword MajorTopicYN="N">Symptoms</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>2</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>1</Day><Hour>18</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>1</Day><Hour>18</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>1</Day><Hour>12</Hour><Minute>18</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39485635</ArticleId><ArticleId IdType="doi">10.17269/s41997-024-00958-7</ArticleId><ArticleId IdType="pii">10.17269/s41997-024-00958-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Biddle, N., &amp; Korda, R. (2022). The experience of COVID-19 in Australia, including long-COVID - evidence from the COVID-19 Impact Monitoring Survey Series, August 2022. Canberra: ANU Centre for Social Research and Methods. https://csrm.cass.anu.edu.au/sites/default/files/docs/2022/10/The_experience_of_COVID-19_in_Australia_-_For_web.pdf . Accessed 3 Jan 2024.</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention. (2023). Post-COVID conditions: Information for healthcare providers. https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-conditions.html . Accessed 3 Jan 2024.</Citation></Reference><Reference><Citation>Government of Canada. (2022a). Federal, provincial, territorial public health response plan for ongoing management of COVID-19. https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/guidance-documents/federal-provincial-territorial-public-health-response-plan-ongoing-management-covid-19.html . Accessed 24 May 2024.</Citation></Reference><Reference><Citation>Government of Canada. (2022b). Tri-Council Policy Statement: Ethical conduct for research involving humans &#x2013; TCPS 2 (2022). https://ethics.gc.ca/eng/policy-politique_tcps2-eptc2_2022.html . Accessed 4 Dec 2023.</Citation></Reference><Reference><Citation>Hedberg, P., &amp; Naucl&#xe9;r, P. (2024). Post-COVID-19 condition after SARS-CoV-2 infections during the omicron surge vs the delta, alpha, and wild type periods in Stockholm, Sweden. Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiad382</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiad382</ArticleId><ArticleId IdType="pubmed">37665981</ArticleId></ArticleIdList></Reference><Reference><Citation>Hertz-Picciotto, I., &amp; Rockhill, B. (1997). Validity and efficiency of approximation methods for tied survival times in Cox regression. Biometrics, 53(3), 1151&#x2013;1156.</Citation><ArticleIdList><ArticleId IdType="doi">10.2307/2533573</ArticleId><ArticleId IdType="pubmed">9333345</ArticleId></ArticleIdList></Reference><Reference><Citation>Jennings, S., Corrin, T., &amp; Waddell, L. (2023). A systematic review of the evidence on the associations and safety of COVID-19 vaccination and post COVID-19 condition. Epidemiology &amp; Infection. https://doi.org/10.1017/S0950268823001279</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0950268823001279</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen, A., Castro, A. W., Ferretti, M. T., Martinkova, J., Vasilevskaya, A., Antonella Santuccione, A., et al. (2022). Sex and gender differences in the neurological and neuropsychiatric symptoms of long COVID: A narrative review. Journal of Sex- and Gender-Specific Medicine. https://doi.org/10.1723/3769.37563</Citation><ArticleIdList><ArticleId IdType="doi">10.1723/3769.37563</ArticleId></ArticleIdList></Reference><Reference><Citation>National Center for Health Statistics. (2023). Long COVID Household Pulse Survey. https://www.cdc.gov/nchs/covid19/pulse/long-covid.htm . Accessed 8 Nov 2023.</Citation></Reference><Reference><Citation>National Institute for Health and Care Excellence (NICE), Scottish Intercollegiate Guidelines Network (SIGN), &amp; Royal College of General Practitioners (RCGP). (2022). COVID-19 rapid guideline: Managing the long-term effects of COVID-19. https://www.nice.org.uk/guidance/ng188/resources/covid19-rapid-guideline-managing-the-longterm-effects-of-covid19-pdf-51035515742 . Accessed 12 Jan 2024.</Citation></Reference><Reference><Citation>Notarte, K. I., de Oliveira, M. H. S., Peligro, P. J., Velasco, J. V., Macaranas, I., Ver, A. T., et al. (2022). Age, sex and previous comorbidities as risk factors not associated with SARS-CoV-2 infection for long COVID-19: A systematic review and meta-analysis. Journal of Clinical Medicine. https://doi.org/10.3390/jcm11247314</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11247314</ArticleId><ArticleId IdType="pubmed">36555931</ArticleId><ArticleId IdType="pmc">9787827</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Mahoney, L. L., Routen, A., Gillies, C., Ekezie, W., Welford, A., Zhang, A., et al. (2023). The prevalence and long-term health effects of long COVID among hospitalised and non-hospitalised populations: A systematic review and meta-analysis. eClinicalMedicine. https://doi.org/10.1016/j.eclinm.2022.101762</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101762</ArticleId><ArticleId IdType="pubmed">37125400</ArticleId><ArticleId IdType="pmc">10115131</ArticleId></ArticleIdList></Reference><Reference><Citation>Perlis, R. H., Santillana, M., Ognyanova, K., &amp; Lazer, D. (2023). Correlates of symptomatic remission among individuals with post-COVID-19 condition. MedRXiv. https://doi.org/10.1101/2023.01.31.23285246</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2023.01.31.23285246</ArticleId><ArticleId IdType="pubmed">38234776</ArticleId><ArticleId IdType="pmc">10793528</ArticleId></ArticleIdList></Reference><Reference><Citation>Pillay, J., Rahman, S., Guitard, S., Wingert, A., &amp; Hartling, L. (2022). Risk factors and preventive interventions for post COVID-19 condition: Systematic review. Emerging Microbes &amp; Infections. https://doi.org/10.1080/22221751.2022.2140612</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2022.2140612</ArticleId></ArticleIdList></Reference><Reference><Citation>Puntoni, M., Esposito, S., Patrizi, L., Palo, C. M., Deolmi, M., Autore, G., et al. (2023). Impact of age and sex interaction on post-acute sequelae of COVID-19: An Italian cohort study on adults and children. Journal of Clinical Medicine. https://doi.org/10.3390/jcm12082924</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm12082924</ArticleId><ArticleId IdType="pubmed">37109260</ArticleId><ArticleId IdType="pmc">10144783</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabe-Hesketh, S., &amp; Skrondal, A. (2006). Multilevel modelling of complex survey data. Journal of the Royal Statistical Society, Series A, 169(4), 805&#x2013;827.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1467-985X.2006.00426.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Robineau, O., Zins, M., Touvier, M., Wiernik, E., Lemogne, C., de Lamballerie, X., et al. (2022). Long-lasting symptoms after an acute COVID-19 infection and factors associated with their resolution. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2022.40985</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.40985</ArticleId><ArticleId IdType="pubmed">36350653</ArticleId><ArticleId IdType="pmc">9647489</ArticleId></ArticleIdList></Reference><Reference><Citation>Shields, M., Connor Gorber, S., Janssen, I., &amp; Tremblay, M. S. (2011). Bias in self-reported estimates of obesity in Canadian health surveys: An update on correction equations for adults. Health Reports, 22(3), 35&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">22106788</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano, J. B., Murthy, S., Marshall, J. C., Relan, P., Diaz, J. V., WHO Clinical Case Definition Working Group on Post-COVID-19 Condition. (2022). A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infectious Diseases. https://doi.org/10.1016/S1473-3099(21)00703-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00703-9</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Statistics Canada. (2023). Canadian COVID-19 Antibody and Health Survey (CCAHS). https://www23.statcan.gc.ca/imdb/p2SV.pl?Function=getSurvey&amp;Id=1480441 . Accessed 3 Jan 2024.</Citation></Reference><Reference><Citation>Swail, H., Murphy, T., &amp; Buckeridge, D. (2023). &#x201c;SARS-CoV-2 seroprevalence in Canada&#x201d;. Borealis, V11, UNF:6:1FET9shnHCpIamsH4skKAw==[fileUNF]. Accessed 20 Dec 2023. https://doi.org/10.5683/SP3/LAEQ5L</Citation></Reference><Reference><Citation>Tsampasian, V., Elghazaly, H., Chattopadhyay, R., Debski, M., Naing, T. K. P., Garg, P., et al. (2023). Risk factors associated with post&#x2212;COVID-19 condition: A systematic review and meta-analysis. JAMA Internal Medicine. https://doi.org/10.1001/jamainternmed.2023.0750</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2023.0750</ArticleId><ArticleId IdType="pubmed">37486646</ArticleId><ArticleId IdType="pmc">10037203</ArticleId></ArticleIdList></Reference><Reference><Citation>von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gotzsche, P. C., &amp; Vandenbroucke, J. P. (2007). The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies. Epidemiology. https://doi.org/10.1097/EDE.0b013e3181577654</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/EDE.0b013e3181577654</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodrow, M., Carey, C., Ziauddeen, N., Thomas, R., Akrami, A., Lutje, V., et al. (2023). Systematic review of the prevalence of long COVID. Open Forum Infectious Diseases. https://doi.org/10.1093/ofid/ofad233</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofad233</ArticleId><ArticleId IdType="pubmed">37404951</ArticleId><ArticleId IdType="pmc">10316694</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu, M. (2014). Analyzing multilevel models with the GLIMMIX procedure. Cary, NC: SAS Institute Inc. Paper SAS026&#x2010;2014.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>